Graviti Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GRAVITI PHARMS, and what generic and branded alternatives to GRAVITI PHARMS drugs are available?
GRAVITI PHARMS has eighteen approved drugs.
There is one tentative approval on GRAVITI PHARMS drugs.
Summary for Graviti Pharms
| US Patents: | 0 |
| Tradenames: | 15 |
| Ingredients: | 15 |
| NDAs: | 18 |
Drugs and US Patents for Graviti Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Graviti Pharms | BUPROPION HYDROCHLORIDE | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 211020-002 | Jan 28, 2019 | AB3 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Graviti Pharms | ATORVASTATIN CALCIUM | atorvastatin calcium | TABLET;ORAL | 209912-001 | Jun 18, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Graviti Pharms | HYDROXYZINE HYDROCHLORIDE | hydroxyzine hydrochloride | TABLET;ORAL | 217652-003 | Aug 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Graviti Pharms | CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 216925-001 | Aug 9, 2023 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Graviti Pharms | FAMOTIDINE | famotidine | TABLET;ORAL | 218461-002 | Mar 14, 2024 | OTC | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
